Literature DB >> 20152762

Patient access schemes for high-cost cancer medicines.

Steve Williamson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20152762     DOI： 10.1016/S1470-2045(09)70402-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  International variability in the reimbursement of cancer drugs by publically funded drug programs.

Authors:  P K Cheema; S Gavura; M Migus; B Godman; L Yeung; M E Trudeau
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

2.  From NCE to NICE: the role of pharmacoeconomics.

Authors:  Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

3.  Value-based pricing: incentive for innovation or zero net benefit?

Authors:  Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

Review 4.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

Review 5.  Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.

Authors:  Szymon Jarosławski; Mondher Toumi
Journal:  BMC Health Serv Res       Date:  2011-10-08       Impact factor: 2.655

6.  Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis.

Authors:  Kyung-Bok Son
Journal:  Global Health       Date:  2020-10-14       Impact factor: 4.185
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.